Medicus Pharma Ltd. Terminates Standby Equity Purchase Agreement with Yorkville

What Happened

• Medicus Pharma Ltd. filed a Form 8‑K reporting that, on September 11, 2026, the company and YA II PN, Ltd. (Yorkville) mutually agreed to terminate the Standby Equity Purchase Agreement (SEPA) dated February 10, 2025. Under the SEPA the company had the right to issue and sell up to $15.0 million of common shares to Yorkville. At termination there were no outstanding borrowings, advance notices or common shares to be issued, and no termination fees are due by either party.

Key Details

• SEPA effective date: originally dated February 10, 2025; termination effective September 11, 2026.
• Facility size under SEPA: up to $15.0 million of common shares.
• At termination: zero outstanding borrowings, zero advance notices, zero shares to be issued, and no fees owed.
• Yorkville Securities, LLC (an affiliate) remains a sales agent under Medicus’s Equity Distribution Agreement dated December 29, 2025 (as amended).

Why It Matters

• This ends a potential source of up-to-$15.0M equity financing that the company previously could draw from Yorkville under the SEPA. For investors, that means one previously available backstop for issuing equity is no longer in place, though there were no draws against it at termination.
• The filing confirms there are no immediate cash obligations or fees tied to ending the agreement and that Yorkville’s affiliate still serves as a sales agent under the company’s separate equity distribution agreement.